Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 13/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 11/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 8/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.37 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15747147 | 0.81 | PIK3CD (0.35) | PIK3CAPIK3CBPIK3CGPIK3CDALDH1A1 | |
| SCHEMBL2756732 | 0.81 | ALDH1A1 (0.36) | PIK3CAPIK3CBPIK3CGPIK3CDALDH1A1 | |
| SCHEMBL10141067 | 0.79 | PIK3CA (0.35) | PIK3CAPIK3CBPIK3CGPIK3CD | |
| SCHEMBL10118799 | 0.77 | KLK7 (0.35) | PIK3CAPIK3CBPIK3CGPIK3CDSCN10A | |
| SCHEMBL12328338 | 0.76 | LMNA (0.36) | — | |
| SCHEMBL9980107 | 0.75 | SCN10A (0.36) | PIK3CAPIK3CBPIK3CGPIK3CDSCN10A | |
| SCHEMBL10119926 | 0.74 | KLK7 (0.33) | PIK3CAPIK3CBPIK3CGPIK3CD | |
| SCHEMBL10147390 | 0.72 | MAOB (0.34) | PIK3CAPIK3CBPIK3CGPIK3CDALDH1A1 | |
| SCHEMBL18948587 | 0.72 | MAOB (0.34) | PIK3CAPIK3CBPIK3CGPIK3CDALDH1A1 | |
| SCHEMBL14311753 | 0.70 | OGA (0.44) | USP2ALDH1A1GAAPKMHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110189129-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110189129-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, HCCS, NSUN2 | PIK3CA 1794/4885PIK3CB 825/4885PIK3CG 912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.